North America Biodefense Market size exceeded USD 6.1 billion in 2021 and is anticipated to exhibit 7.5% CAGR between 2022 and 2028.

Increasing government initiatives will drive the overall market expansion. The U.S. government is taking numerous efforts for the characterization of threat, risk assessment, medical countermeasures, detection, and surveillance of infectious disease along with laboratory protection from accidental exposures. Similarly, government is also taking initiatives for the awareness among large population base regarding bioterrorism incidences majorly in developed countries.

Get more details on this report - Request Free Sample PDF

In bioterrorism attack, infectious viruses, bacteria, and other germs are released to cause illness, diseases. and death. Therefore, to overcome these attacks, the government is taking bio defensive measures, mainly vaccines and biothreat detection technology efforts for the safety of the population.

North America Market, By Product

Get more details on this report - Request Free Sample PDF

The vaccines segment accounted for USD 4 billion revenue in 2021, owing to the rising vaccine production to prevent various diseases. Surging prevalence of infectious diseases such as COVID-19, Ebola virus and Zika virus has increased the demand of vaccines. Therefore, to overcome the rising number of infectious cases researchers are inspecting new vaccine technologies including vector technology to protect against these pathogenic attacks.

North America Market, By Country

The U.S. biodefense market will showcase around 7.5% growth rate during the forecast period. The U.S. market consists of well-known and established firms with approved government policies within the healthcare industry. This increases the production of various vaccines for the biodefense market. The U.S. government mainly focuses on several initiatives against bioterrorism attacks with strong security measures that secures the country-level progression. Moreover, increasing adoption of advanced technological products used for biodefense purposes across the region will accelerate the market growth.

Competitive Industry Landscape

Some of the leading companies involved in the North America biodefense market include Bavarian Nordic, Biosearch Technologies, Alexeter Technologies, LLC, ANP Technologies, Altimmune, and BioFire Defense (bioMérieux SA).

These market players have adopted different strategies such as launch of new products with technological advancements that have helped them in sustaining the competition and gain significant position in the industry. For instance, in February 2022, Applili Tehrapeutics Inc., received around USD 10 million in new funding from the U.S. department of defense for biodefense vaccine candidate ATI-1701. This novel strategic move will enhance the company’s progress over the analysis timeframe.